Inhibition of immune responses by Dasatinib may account for its different effects on neuroblastoma between in vitro and in vivo.
Chen
Jiezhong
J
D000818:Animals; D000069439:Dasatinib; D006801:Humans; D007111:Immunity, Cellular / Q000187:drug effects*; D009447:Neuroblastoma / Q000188:drug therapy* / Q000276:immunology* / Q000473:pathology; D047428:Protein Kinase Inhibitors / Q000494:pharmacology*; D011505:Protein-Tyrosine Kinases / Q000037:antagonists & inhibitors; D011743:Pyrimidines / Q000494:pharmacology*; D013844:Thiazoles / Q000494:pharmacology*
D047428:Protein Kinase Inhibitors; D011743:Pyrimidines; D013844:Thiazoles; D011505:Protein-Tyrosine Kinases; D000069439:Dasatinib